Description
PrymaLab · Research Use Only
Mazdutide 10mg
Built on a hormone that already engaged both receptors
Mazdutide engages two receptors, and so do several other compounds in this catalogue. The difference is where it came from. The others were built by combining features of two hormones into one chain. This one is an analogue of a peptide that already engaged both, which is a different design problem with a different set of consequences.
Specification Table
| Property | Value |
|---|---|
| Compound | Mazdutide |
| Development codes | LY3305677 and IBI362 |
| Class | Synthetic analogue of mammalian oxyntomodulin |
| Parent peptide | Oxyntomodulin, a 37 residue product of proglucagon processing |
| Why the parent matters | Oxyntomodulin engages both receptors natively. It is not an engineered combination |
| Modification | A fatty acid side chain, the standard approach to extending circulation time |
| Reported targets | The GLP-1 receptor and the glucagon receptor |
| Dosing interval in published work | Once weekly, which is what the acylation is for |
| Molecular weight | Read from the lot certificate. Acylation and salt form both change the figure |
| Originator | Eli Lilly, with China rights licensed to Innovent Biologics in 2019 |
| Regulatory status | Approved in China in June 2025 for chronic bodyweight management |
| Status elsewhere | Not approved in the United States or the European Union |
| Evidence base | Predominantly Chinese trial populations across phase 1, 2 and 3 |
| Vial | 10mg lyophilized |
| Storage | Sealed at minus 20°C. Do not freeze reconstituted solution and do not agitate |
Why Does the Oxyntomodulin Scaffold Matter?
The mazdutide scaffold starts with proglucagon, a precursor protein cut into several different peptides depending on which tissue is doing the cutting.
One of the products is oxyntomodulin, a 37 residue peptide released from the gut after a meal.
Oxyntomodulin engages both the GLP-1 receptor and the glucagon receptor natively. Nobody designed it to.
That is unusual, and it is the reason the scaffold was attractive to whoever designed mazdutide.
The alternative route to a dual agonist is to build a chimera: take sequence features that drive engagement at one receptor, combine them with features that drive engagement at the other, and iterate until both work at usable potency.
Chimeric design is difficult because the two sets of features compete for the same positions in a single chain, and improving one arm frequently degrades the other.
Starting from a peptide that already does both removes that problem at the outset. The design work becomes optimisation rather than construction.
Pocai reviewed the biology of the parent peptide and the case for developing analogues of it, and the argument in that review is essentially the one this compound was built on.
The cost is that the natural balance between the two receptor arms is inherited rather than chosen, and adjusting it means moving away from the scaffold that made the design easy.
It is worth being clear about what the scaffold argument does and does not establish.
That a natural peptide engages two receptors is a fact about the peptide.
It is not evidence that engaging both is useful, and it is not evidence that the ratio nature settled on is the right one for any particular purpose.
The scaffold made the chemistry tractable. Whether the pharmacology is desirable is a separate question and it is the one the clinical programme has been answering.
What Does the Acylation Do?
Native oxyntomodulin is cleared quickly. That is normal for a gut peptide and useless for a compound like mazdutide intended to act over a week.
A fatty acid side chain attached through a linker addresses that, and the mechanism is well established across this class.
The chain promotes reversible binding to serum albumin, and peptide bound to albumin is protected from renal filtration and from peptidase access.
The bound and free forms exchange continuously, so the albumin population acts as a reservoir that releases free peptide slowly.
The published work reports once weekly intervals.
For laboratory work the mazdutide acylation has consequences that have nothing to do with circulation time.
A fatty acid chain makes the molecule surface active, so it accumulates at air-liquid interfaces and adsorbs to container walls more readily than an unmodified peptide.
It also raises the tendency to self-associate, since hydrophobic chains find one another in aqueous solution.
Both of those are handling problems rather than pharmacology problems, and both are worse at the low concentrations a receptor assay works at.
What Does Engaging Two Receptors Change?
The two mazdutide receptor arms are associated with different physiology, and combining them is the whole premise.
One is engaged by a hormone associated with reducing intake. The other is engaged by a hormone historically associated with raising circulating glucose.
Putting those together looks contradictory at first reading, and the argument for it rests on the glucagon arm contributing to energy expenditure rather than only to glucose output.
Whether that balance is favourable across a population is what the clinical programme has been testing, and it is not a settled question in the general case.
For an experiment the important consequence is the familiar one. A dual agonist cannot be used to attribute an effect to a single receptor.
Any observed change has two candidate routes, and separating them requires a receptor-null system or a selective antagonist run alongside rather than the compound on its own.
The relative potency at the two receptors is a property of the specific analogue rather than of the class, so a design that worked to separate the arms for one compound will not necessarily work for another.
That figure should be read from the primary characterisation rather than carried across from a sibling molecule.
Where Does the Evidence Actually Come From?
This is the part of the mazdutide record most likely to be missed by a researcher searching in English, and it is not a minor detail.
Mazdutide originated at Eli Lilly and China rights were licensed to Innovent Biologics in 2019. Innovent has run the development programme since.
The trials have been conducted in China with Chinese participants, across phase 1, phase 2 and phase 3.
Approval followed in China in June 2025 for chronic bodyweight management, which made this the first dual GLP-1 and glucagon receptor agonist approved anywhere.
It is not approved in the United States or the European Union.
The consequence for reading the literature is concrete rather than abstract.
Baseline characteristics differ between the trial populations here and those in the Western programmes for comparable compounds, and body mass index thresholds used for enrolment in the Chinese studies are lower than those conventional elsewhere.
Ji and colleagues published the phase 1b work in 2021 and the phase 2 results in 2023, and both describe the population explicitly.
Comparing a figure from this programme against a figure from a Western trial of a different compound is comparing two things that differ in more than the molecule, and the comparison is made constantly.
A practical note on how to search this literature, since the naming makes it harder than it should be.
Three designations are in active use: the current name, the Lilly code and the Innovent code.
Papers from the earlier phases are indexed under the codes and papers from the later ones under the name, so a search on any single term returns a partial record.
Running all three and keeping the union is a few minutes of work at the start of a project.
What Should a Mazdutide Certificate Show?
The full mazdutide sequence written out, with the position of the fatty acid attachment stated.
Observed mass by spectrometry, since incomplete acylation is a real synthesis failure and produces a species with a distinct and predictable mass difference.
Purity by chromatography with the method named.
Aggregate content by size exclusion chromatography, which matters more on an acylated peptide than on an unmodified one.
Net peptide content and the salt form, because the vial mass includes counterion.
Appearance of the reconstituted solution, described rather than assumed.
Lot number and manufacturing date.
The acylation position is the field most often reduced to a single word. A certificate stating that the molecule is acylated, without saying where, has described a class rather than a compound.
How Should the Vial Be Handled?
Mazdutide has a handling profile closer to a formulated protein than to a short synthetic sequence.
Sealed lyophilized material holds at minus 20 degrees Celsius, kept dark and dry.
Bring the vial to ambient temperature before opening, then reconstitute by adding diluent down the wall and allowing the cake to dissolve without agitation.
Do not vortex and do not shake. A surface active molecule driven to an air-liquid interface can associate there, and the association is not always reversible.
Do not freeze a reconstituted solution. Ice formation concentrates the peptide in the shrinking liquid phase, which is the wrong direction for anything prone to self-association.
Aliquot on first reconstitution so the working stock is opened once.
Use low-binding consumables throughout. Adsorption losses on an acylated peptide at assay concentrations are large enough to move a reported potency figure.
Consider the diluent deliberately rather than by habit, since a preserved diluent introduces a small hydrophobic molecule into a solution already containing a hydrophobic chain.
Record lot, net peptide content, the diluent and its preservative status, storage temperature, the date of reconstitution and any aggregate figure measured.
Reconstitution date belongs on that list. Time in solution is where an acylated peptide loses material quietly.
One last point on why the diluent choice is called out here rather than left as a default.
This catalogue also sells a preserved diluent, and preserved means benzyl alcohol.
Adding a small hydrophobic molecule to a solution of a peptide carrying a fatty acid chain is not obviously harmless, and the published work on preservative interactions concerns exactly this kind of pairing.
It is not a reason to avoid the preserved diluent categorically. It is a reason to decide rather than to reach for whichever vial is nearest.
Published Literature
Selected references on the parent peptide, on the published clinical programme for this analogue and on peptide storage generally.
- Pocai A. Molecular Metabolism. 2014;3(3):241-251. PMID: 24749050
- Ji L, Jiang H, An P, Deng H, Liu M, Li L, et al. eClinicalMedicine. 2021;39:101088. DOI: 10.1016/j.eclinm.2021.101088
- Ji L, Jiang H, Cheng Z, Qiu W, Liao L, Zhang Y, et al. Nature Communications. 2023;14(1):8289. DOI: 10.1038/s41467-023-44067-4
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Pharmaceutical Research. 2010;27(4):544-575. DOI: 10.1007/s11095-009-0045-6
Frequently Asked Questions
What is mazdutide?
Mazdutide is a synthetic analogue of oxyntomodulin carrying a fatty acid side chain, known in the literature as LY3305677 and IBI362. It engages the GLP-1 receptor and the glucagon receptor.
What is oxyntomodulin?
A 37 residue peptide produced by proglucagon processing and released from the gut after a meal. It engages both receptors natively rather than by design.
Why does starting from a natural dual agonist help?
Because chimeric design requires features driving engagement at two receptors to share one chain, and improving one arm often degrades the other. A native scaffold removes that problem at the outset.
What does the scaffold cost?
The balance between the two receptor arms is inherited rather than chosen, and that inheritance is fixed. Adjusting it means moving away from the scaffold that made the design straightforward.
What does the fatty acid chain do?
It promotes reversible binding to serum albumin, which protects the peptide from renal filtration and peptidase access. Published work reports once weekly intervals as a result.
Does the acylation affect handling?
Considerably. It makes the molecule surface active, so it accumulates at air-liquid interfaces, adsorbs to container walls and self-associates more readily than an unmodified peptide.
Can an effect be attributed to one receptor?
Not from the compound alone. Any observed change has two candidate routes, and separating them requires a receptor-null system or a selective antagonist run alongside.
Where was it developed?
Mazdutide originated at Eli Lilly, with China rights licensed to Innovent Biologics in 2019. Innovent has run the programme since.
Is it approved anywhere?
Yes. China approved it in June 2025 for chronic bodyweight management, which made it the first dual GLP-1 and glucagon receptor agonist approved anywhere. It is not approved in the United States or the European Union.
Why does the trial population matter?
Because baseline characteristics and enrolment thresholds differ from those used in Western programmes for comparable compounds, so a cross-programme comparison differs in more than the molecule.
What should the certificate state about the acylation?
Where the fatty acid is attached, not merely that it is. Incomplete acylation is a real synthesis failure with a predictable mass difference, so observed mass matters here.
What is the quiet failure mode in solution?
Adsorption and self-association driven by the lipid chain. Neither is visible, and both reduce the monomeric peptide available while leaving the nominal concentration unchanged.
Compliance Statement
Mazdutide is sold exclusively for laboratory research use. It is not a drug, food, or cosmetic product, and it is not a dietary product of any kind. It is not approved by the FDA or any comparable authority for human or veterinary use, its approval is held in a single jurisdiction and does not extend to the United States or the European Union, its published evidence base was generated almost entirely in Chinese trial populations with enrolment criteria that differ from those used elsewhere, it engages two receptors so published findings cannot be attributed to one of them, and no compound in this range is offered for any human or veterinary purpose. This product is not intended to diagnose, treat, cure, or prevent any disease. It must not be given to humans or animals. Purchase is restricted to qualified researchers and institutions operating within applicable laws. All handling is the responsibility of the purchasing laboratory.
19 reviews for Mazdutide 10mg